significantDiagnostic advance
VEGF validated as reliable response biomarker across treatment modalities
POEMS Syndrome →Summary
Accumulating evidence confirms that plasma VEGF levels track treatment response across all modalities (ASCT, lenalidomide, bortezomib, radiation). Pre-transplant VEGF response predicted superior 5-year PFS (90.9% vs 47.4%). Plasma VEGF (rather than serum) is preferred to avoid platelet-derived confounding.
More from POEMS Syndrome
significantTreatment update
Daratumumab emerging as treatment option for relapsed POEMS
incrementalTreatment update
Improved transplant outcomes in the modern era
incrementalTreatment update
Lenalidomide plus dexamethasone long-term data confirm durable responses
significantNew research
Single-cell analysis reframes VEGF pathogenesis: plasma cells produce IL-6, not VEGF
ID: poems-syndrome-update-1Type: diagnostic_advanceImpact: significant